Published in Vaccine Weekly, April 23rd, 2003
According to recent research from Italy, "Recent experimental evidence shows that vaccination with amyloid-beta peptide (A-beta) of transgenic mouse models of Alzheimer's disease protects from the pathological accumulation of amyloid within the CNS. Phase I/II clinical trials of A-beta vaccination in mild to moderate Alzheimer's disease have been undertaken. Unexpectedly, one of these trials has been suspended because 15 patients showed clinical signs consistent with CNS inflammation."
"Here, we show that C57BL/6 mice immunized with A-beta1-42 peptide...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly